I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

Immuno-oncology (IO) drugs or cancer therapeutics represent one of the most promising areas of medical innovation in the next ...

Anti-obesity medications are often used to help people who have tried and not been able to lose enough weight through exercise and dietary changes. Obesity is a widespread issue affecting over 40% ...

Use of anti-obesity drugs, including GLP-1RAs, was associated with reduced alcohol consumption among participants in a telehealth weight management program. Anti-obesity medication (AOM) initiation is ...